BioAge Labs, Inc. (NASDAQ: BIOA) reported results from a phase 1 clinical trial of BGE-102, an oral NLRP3 inhibitor, showing ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE